However, we also observed significant upregulation of RUNX1 in the cancer cells of replacement HGP CRCLM lesions that are typically resistant to the combination of chemotherapy with bevacizumab (Chemo + bev) (Supplementary Fig. 1a). This evidence concerns the gene RUNX1 and cancer.